PMC:4693303 / 24570-25719 JSONTXT

{"project":"TEST0","denotations":[{"id":"26752867-149-154-1465727","span":{"begin":192,"end":193},"obj":"[\"25538455\"]"},{"id":"26752867-235-241-1465728","span":{"begin":857,"end":859},"obj":"[\"25972518\"]"},{"id":"26752867-233-239-1465729","span":{"begin":1004,"end":1006},"obj":"[\"25972518\"]"}],"text":"BLOOD OR PLASMA TRANSFUSION FROM SURVIVORS\nAnother promising treatment option reviewed in this group's previous article was a transfusion of blood or plasma from convalescent Ebola survivors.[1] It is noteworthy to mention that whole-blood or plasma transfusion therapy was determined to be ethically acceptable by the WHO during the 2014-2015 outbreak, provided that certain risk-benefit elements are taken into consideration by the treating healthcare team.[60] Specific safety and ethical considerations include donor testing for EBOV RNA (must be negative on two independent blood draws conducted at least 48 h apart) and testing of the donated blood for donor-recipient compatibility and blood-borne infections. This general consideration also implies a requirement for facilities that are able to properly handle and process blood and blood products.[56] Donated blood may vary in protective efficacy because neutralizing antibodies may take several weeks to months to appear at sufficient levels.[56] Clinical research is underway to determine if there are benefits associated with such transfusion therapy in the setting of EBOV disease.[58]"}

{"project":"2_test","denotations":[{"id":"26752867-25538455-60482793","span":{"begin":192,"end":193},"obj":"25538455"},{"id":"26752867-25972518-60482794","span":{"begin":857,"end":859},"obj":"25972518"},{"id":"26752867-25972518-60482795","span":{"begin":1004,"end":1006},"obj":"25972518"}],"text":"BLOOD OR PLASMA TRANSFUSION FROM SURVIVORS\nAnother promising treatment option reviewed in this group's previous article was a transfusion of blood or plasma from convalescent Ebola survivors.[1] It is noteworthy to mention that whole-blood or plasma transfusion therapy was determined to be ethically acceptable by the WHO during the 2014-2015 outbreak, provided that certain risk-benefit elements are taken into consideration by the treating healthcare team.[60] Specific safety and ethical considerations include donor testing for EBOV RNA (must be negative on two independent blood draws conducted at least 48 h apart) and testing of the donated blood for donor-recipient compatibility and blood-borne infections. This general consideration also implies a requirement for facilities that are able to properly handle and process blood and blood products.[56] Donated blood may vary in protective efficacy because neutralizing antibodies may take several weeks to months to appear at sufficient levels.[56] Clinical research is underway to determine if there are benefits associated with such transfusion therapy in the setting of EBOV disease.[58]"}